Partnering with FEMS
FEMS is a unique, active and diverse network of around 30,000 professionals who are committed to advancing microbiology for the benefit of society in the areas of health, energy, food, materials and the environment. Set up in the UK as a small charity in 1974, today we are a growing coalition of 54 Member Societies from 38 countries across Europe. Many of those in our network are early career researchers. Others are experienced scientists, industry professionals, students and campaigners.
See our Partnership Opportunities handout for more information.
The aim of this study was to determine whether in vitro induced erythromycin resistance facilitates the cross-resistance to the novel fluoroketolide, solithromycin, in Staphylococcus aureus. Long-term exposure of erythromycin results in resistance to ketolides in S. aureus through drug binding site mutations. These results demonstrate that since erythromycin has been used clinically for a long time, it is necessary to carefully evaluate the rewards and risks when prescribing solithromycin for the treatment of infectious diseases.